regulation is the sole category represented across all 1 tracked stories. MHRA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 7 runs above the beat's 5.7 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Rare Cancers Law
regulation is the sole category represented across all 1 tracked stories. MHRA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 7 runs above the beat's 5.7 for that window. Source depth averages 4 original sources per story, versus 3.2 across the same-window beat baseline. Rare Cancers Law appears in 1 tracked Healthcare story from February 27, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Rare Cancers Law. Shared-story counts are live from our verified record — not editorial picks.
The UK government is advancing a draft Rare Cancers Law designed to fast-track treatments and research for patients with incurable brain tumors. This legislative push aims to dismantle bureaucratic barriers that have historically hindered drug development and clinical trial access for rare oncological conditions.
Rare Cancers Law is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.